{"entity":{"id":"nct03653507","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","aka":[],"tldr":"A phase 3 trial of Zolbetuximab, Oxaliplatin and Capecitabine in gastric & gastro-oesophageal junction cancer, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.","summary":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). is a phase 3 interventional study registered as NCT03653507 by Astellas Pharma Global Development, Inc., with 507 participants enrolled, started 2018-11-28 and due to reach its primary completion in 2022-10-25. Interventions recorded: zolbetuximab, oxaliplatin, capecitabine and placebo. Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03653507","url":"https://clinicaltrials.gov/study/NCT03653507"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["zolbetuximab","oxaliplatin","capecitabine"],"companies":["astellas"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03653507","phase":"3","setting":"A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","sponsor":"Astellas Pharma Global Development, Inc.","enrolled":507,"outcomes":[]},"route":"/trials/nct03653507/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"},{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/"}],"company":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/"}]}}